New combo therapy shows promise for rare blood cancer
NCT ID NCT04127227
First seen Mar 16, 2026 · Last updated Jun 18, 2026 · Updated 15 times
Summary
This study tests a new treatment for people with a rare and aggressive type of lymphoma (NK/T-cell lymphoma) that has spread. The treatment combines an immunotherapy drug (sintilimab) with a chemotherapy regimen (P-GemOx). The goal is to see if this combination is safe and effective at shrinking or eliminating tumors. The study involves 34 adults who have not received prior treatment for their advanced disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK/T CELL LYMPHOMA NOS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 51000, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.